Article
APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease.
Human mutation - 1 Aug 2009
Bettens Karolien, Brouwers Nathalie, Engelborghs Sebastiaan, Van Miegroet Helen, De Deyn Peter P, Theuns Jessie, Sleegers Kristel, Van Broeckhoven Christine
Abstract excerpt
Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression. In a well-characterized Belgian group of 358 AD patients and 462 controls, we examined whether genetic variability in microRNA (miRNA) binding sites of APP and BACE1 or in associated miRNAs influenced risk for AD. Direct sequencing identified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.